ImStem was incorporated in 2012

As an innovative biopharmaceutical company,
we aspire to improve patients' treatment outcomes
and quality of life, targeting areas in autoimmune,
degenerative, and rare diseases.

T-MSC

T-MSC is based on ImStem’s patented technology,
which can differentiate human embryonic stem
cells (hESCs) into mesenchymal stem cells (MSCs)
with high efficiency, consistency, and quality,
through a trophoblast-like intermediate stage.

The MSC derived with this proprietary technology
is called T-MSC.

Currently the clinical trial to study the proprietary T-MSC (IMS001) cell therapy in patients with multiple sclerosis is under way. IMS001 is a human embryonic cell (hESC) derived mesenchymal stem cell (MSC) investigational drug.

A clinical trial to study the proprietary T-MSC (IMS001) cell therapy in patients with multiple sclerosis is ongoing. IMS001 is a human embryonic (hESC) derived mesenchymal stem cell (MSC). The Phase 1/2a study is enrolling multiple sclerosis patients who meet the following criteria: